Our team got FUNDED 💰 for (my first) phase 1 clinical trial focused on esophageal cancer 💊 🩼!!
Extremely thrilled and excited for this amazing opportunity! 🏆 So looking forward to my final year of oncology fellowship.
@UIowaCancer
@AdamMGrant
You should only focus on getting high USMLE scores was the worst advice I ever got! Glad I chose not to follow it! I am so happy I broadened my horizons, did community work, did a research year and started residency at a wonderful program this July!
Today was the highlight of my first year of fellowship so far. Felt like I just watched my fav movie! Excellent lecture on “How to Critically Evaluate Clinical Trials” by the one and only
@VPrasadMDMPH
! I’ll def have way more questions to ask, when I read a clinical trial now.
Presenting our work on primary care access and colorectal cancer-related mortality at
#AACR2023
. Most cancers aren’t diagnosed at cancer centers! The dialog around early detection is incomplete until we adequately address primary care access, especially among racial minorities.
Re-sharing our commentary on the struggles of FMGs training on J1 visas. About time we addressed the need for extended J1 visas (covering the duration of training) and fair employment opportunities. This IS a part of physician well-being! 🇺🇸 🌎
Link👉🏽
I am so humbled to receive the best oral presentation award (clinical) at the annual
@NANETS1
symposium. Thank you Dr
@PoHienEar
for receiving the award on my behalf. This is all because of my amazing mentor
@ChandrikhaC
- thank you for everything! and Dr Joe Dillon
@UIowaCancer
.
Final day at my VA continuity clinic today!
#bittersweet
It’s been a wonderful experience taking care of our veterans at the Iowa City VA Medical Center.
Looking back, this was one of the best decisions I took- requesting my chiefs to have my continuity clinic at the VA. I
Third and final year of fellowship starts today. Time to update my Epic signature!
Congratulations to new interns and fellows across the nation and also others who are climbing up the ladder in their residency/fellowship training.
I feel supremely fortunate to have the
With the rising ⭐️ in lymphoma and cellular therapy
@AgrimaMianMD
!
@CleClinicMD
is so lucky to have an amazing resident and a superbly talented rising H/O fellow! I’m lucky to call you a friend. So proud of all the fantastic work that you have done so far.
#ASHkudos
#ASH22
Had a wonderful experience delivering my oral presentation at
@NANETS1
annual meeting today, discussing
@UIowaCancer
experience with repeat PRRT ☢️ in advanced G1-2 NETs 🦓Thanks to my amazing mentor
@ChandrikhaC
and Dr Dillon
@IntMedatIowa
for all the support!
Poster
#439
- We looked at characteristics and outcomes in pts with young-onset cholangiocarcinoma. We noted better survival (despite ⬆️ stage) and ⬆️ odds of receiving cancer 💉💊 🔪 among YOCCA (more males, iCCA and non-Whites).
#ASCO2023
@UIowaCancer
@IntMedatIowa
#ASCO23
Congratulations to my mentor
@ChandrikhaC
for being awarded the faculty teacher of the year (2024) award at
@UIowaCancer
fellowship graduation. I’m truly grateful to have the opportunity to train and flourish under your mentorship.
@IntMedatIowa
Our team’s poster on content analysis of pancreatic cancer conversations on Twitter (11040).
#ASCO20
We used an online analytical tool to study the content and dynamics of
#PanCan
conversations on Twitter over last 2 years.
The metric is just not the same for IMGs. “Publish or perish” is often quoted as a mantra that one needs to follow in order to stay relevant in academia. While many astute clinicians also publish prolifically, no. of pubs def should not become a surrogate for overall competence.
I had zero publications when I applied to residency (even when I applied to fellowship still 0) as I was too busy learning how to take care of patients.
🔥Hot off the press-
Happy to share our real world post-marketing pharmacovigilance analysis on hematological toxicities (focus on MDS/AML) with Lutathera (Lu177-DOTA-TATE) in 🇺🇸 .
👉🏽Post-marketing surveillance data from the
@US_FDA
(2018-2023)
👉🏽 3443 adverse events, 243 (7.1%)
One of the best things about being a fellow
@UIowaCancer
is getting to work with and mentor
@IowaMed
med students.
Rockstar 🌟 MS3 Srija Manchkanti presenting our work at
#ASCO24
.
Outcomes in cholangiocarcinoma in primary sclerosing cholangitis. Manuscript coming out 🔜
👇 Matt and I met >1 year ago at
@UIowaCancer
. Matt, a PhD in cardiovascular physiology was looking for an oncology fellow to collaborate with. 1 yr later, we got funded!!! We will be studying hypertension in young adults with acute leukemia. Thanks to
@GrerkS
for everything!
Dr.
@grewaludhayvir1
at
#GI22
#pancsm
His idea and work, start to finish!
@UIowaCancer
lucky to get him as a Fellow in July.
From 1995-2020, only 11% of pancreatic cancer trials incorporated PROs as (any planned) endpoint
Reporting/ publishing even ↓
Loudest cheer for our NET 🦓 pts! Finally a PRRT RCT for G3! NETTER-2 for 1L PRRT (Lu177) in high G2, G3 GEP NETs (Ki67 10-55%). ORR 40% with sig ⬆️ OS ( 22.8 vs 8.5 mos). Well tolerated, 0.7% long term hem tox, QOL maintained. Absolutely ❤️ the trial design. So thoughtful!
#GI24
As a trainee approaching the half way mark of fellowship training, I continue to reflect on my journey so far as I try to find purpose in what lies ahead of me. It always amazes me how despite all the challenges, there’s always more in life to be grateful for. Happy thanksgiving!
Fanboy moment! Super stoked to have met the legendary
@VincentRK
and someone who I learn hematology from everyday-
@AaronGoodman33
over dinner. Thank you
@chadinabhan
for this amazing opportunity. We need Dr. Soo Park to join Twitter and share her amazing work with
#MedTwitter
So looking forward to ASCO 2024! The badge just arrived in the mail. Can’t wait for all the amazing science and for catching up with new and old friends 😊
#ASCO24
@ASCO
@UIowaCancer
The NET 🦓 enthusiast in me is eagerly waiting for the oral presentation at
#GI24
on the phase 3 NETTER-2 study investigating Lutathera ☢️ in newly diagnosed advanced grade 2 and grade 3 WD GEP-NETs.
#theranostics
Proud to share that I will be representing
@LSUHS_IM
at the
@ASH_hematology
annual meeting this year to present our team’s work on heparin induced thrombocytopenia. My first stint with hematology!
@LSUHS
@LSUHSResearch
Today was the first day I introduced myself as a
#neurosurgery
resident
It’s been a tough journey and I’m am filled with gratitude for all the good people and blessings in my life
If you are on the same journey and applying NSGY, I am happy to help! Please DM!
@IowaNeurosurg
Late-ish news but I’m elated to share that
@IowaMed
MS3 Srija Manchkanti will be presenting our work on cholangiocarcinoma in primary sclerosing cholangitis at
#ASCO24
@UIowaCancer
@curecc
. So proud to be her peer mentor! 🏆
Very intrigued by this new entity described in
@BloodJournal
called Monoclonal gammopathy of thrombotic/thrombocytopenic significance published by
@AnandPheresisMD
et al. Wondering if this is what some of our “spontaneous HIT/VITT” patients really had?
Nobody ever achieved great success by constantly chasing external validation. At some point, you’ve got to stop seeking validation from others, have faith in your vision and keep going; even if nobody is watching.
Not today impostor syndrome! 💪🏻😏
Bittersweet last day in breast oncology clinic with the best team ever. Thanks for all the great learning, diverse clinical experience and coffee/cookies runs
@NicoleFleege
! Loved every bit of it. Always a great time with my buddy and co-fellow
@gkirkpatrick7
. Thanks Sydney and
Are DOACs effective for treatment of VTE in patients with BMI>40? We (
@JashwanthGadda2
et al) published data from
@LSUHS
indicating risk of VTE recurrence is similar b/w DOACs and Warfarin. This is in line with the updated
@isth
guidelines.
My first interview for fellowship at
@IntMedatIowa
was with
@PerepuUsha
. It was crazy that we ended up talking about heparin-induced thrombocytopenia for a good 7 minutes during that interview. We will miss you dearly, Dr Perepu! Good luck with your new role at
@TheLongSOM
I was blown away by the masterful presentation on IO outcomes in lung cancer by Arushi Saini, med student and research fellow
@DanaFarber
. I had to ask her twice if she wasn’t lying about not being a thoracic oncologist 😅Truly inspired 🏆 !
@BiagioRicciutMD
@DrMarkAwad
#ASCO24
Excellent session by my mentor
@ChandrikhaC
on updates in GI malignancies. I’m stoked about the advances in
#precisiononc
in GI cancers. The “practice challenging” NORPACT study is perhaps the most intriguing update in PDAC in the recent times.
#ASCO23
@UIowaCancer
@IntMedatIowa
This
#GI24
meeting is heavy on ctDNA. Looking forward to some exciting data advancing the use of ctDNA for treatment selection and prognostication in GI cancers. One of my favorite reviews on the topic by Dr Alese et al
It’s always REVIEWER 2 who’s having a bad day and ends up choosing the worst possible adjectives to describe a study put together with a lot of effort and sincerity by the investigators.
Please choose your words kindly 🙏🏻
You can certainly critique a paper without being rude! 😊
One of the best things I’ve learnt from my mentor is to ask patients- “how much would you like to know?”. Some pts just wanna know “what’s next/ when can we get started”. Perhaps good doctors don’t just know WHAT to say, but also WHEN to say it and HOW much.
#fellowshiplessons101
Keynote lecture by
@KimmieNgMD
on EOCRC.
- ⬆️ incidence 🐘 in the room!
-Delays in diagnosis common
-Most are sporadic.
-Complex interplay of diet and lifestyle factors.
-Imp to look for targetable 🧬
- ⬆️ treatment ❎ translate into better OS, we need newer strategies!!
#GI24
@BIGtrapmitch
@AdamMGrant
As much as good scores can take you places, there’s so much more that a doctor needs to be and can be! I wanted to foray into the unknown- I started research! I wanted to connect with people- began volunteering!was more attracted to Medicine that was happening outside textbooks!
We now have a weekly “fellows’ forum” at
@UIowaCancer
fellowship program, an endeavor by the first year fellows to casually (the key word) chat about important topics. Today, my amazing colleague
@madala_sam
gave us an excellent talk on early stage TNBC. cc:
@GrerkS
@NicoleFleege
Three important drug-drug interactions to watch out for with capecitabine (list not comprehensive, there could certainly be many others):
👉🏽Warfarin: exaggerated anticoagulant activity. Closely monitor INR, adjust warfarin doses accordingly. Switch to DOAC if no clear
“I’m not that person you see in that picture on my chart anymore” quipped my patient. Cancer changes the lives of our patients completely and many a time permanently! It’s practically impossible for us as physicians to understand the actual impact of this diagnosis on their lives
Presented our work on over-testing among patients w/ heparin induced thrombocytopenia at the Annual American Society of Hematology Meeting, 2021. Finally got to be in one frame with the smartest hematologist that I’ve ever come across-Dr. Ramadas!
@LSUHS_IM
@LSUHS
@LSUHSResearch
Thrilled to share our
@UIowaCancer
experience with repeat beta PRRT 🦓. Link-
So grateful to my mentors Dr
@ChandrikhaC
and Dr Dillon. I’m geared up for more exciting research from our NET team.
It’s really something when the barista at your hospital cafeteria knows your order, sees you in the queue and has it ready by the time you get to the cashier. Unbeatable efficiency 😅💯☕️
Finally found my way to the breast cancer clinic to learn from the coolest and the best breast oncologist
@NicoleFleege
! I’m glad I’m not as intimidated by the volume of breast cancer data now. So grateful for wonderful teachers. 💪🏻🙏🏻
#MedTwitter
#onctwitter
#AHA22
Latest from the
@drpaari
lab!
@habdulja
presenting our work on incidence and predictors of CICM in African American patients with doxorubicin and trastuzumab. Bottom line- need to look beyond traditional risk facfors!
@AHAMeetings
Annual Meeting 2022
@LSUHS_IM
@LSUHS_CCDS
Our recent analysis led by
@IntMedatIowa
resident
@Onc_A_Doc
highlights the need for easily readable and comprehensible online patient education material for our NET patients (in compliance with the NIH guidelines for readability). 🦓 🖥️ 📖
@LACNETS
I know first hand- someone close to me who is on tagrisso in India and is on the verge of applying for a loan in order to remain on therapy. We have a long way to go in the pursuit of global equity in cancer care.
#globaloncology
#financialtoxicity
The “others” in clinical trials include my middle class pensioner parents in India who could never afford these cancer 💊 if they ever needed it! Food for thought as we debate/discuss/plan for Equity as Oncologists!
#GlobalOncology
#lcsm
#ASCO23
So excited to start our fellowship with our inaugural class that matched with us today including
@AakashRSheth
, Saket Komanduri, Mahmoud Salem, and Vivek Verma!!
#FellowMatch
Read this wonderful and eloquent piece in
@OncLive
by
@doctorC369
about NA IO in early-stage dMMR CRC. Perhaps one of the most well-written pieces I have read in recent times. Wonderfully explained. Excited to see the field advance in this direction.
ER eval for chest pain on 5-FU pump is paramount, although it’s almost always good ole prinzmetal angina. Excellent work
@aryandevmehta
! Proud of you.
Excellent virtual lecture on reimagining clinical trials in
#precisiononc
era by the amazing Dr
@Dr_R_Kurzrock
this morning. Truly inspirational! It was really an “avalanche of wisdom” as it was described by the audience. Thanks
@ZakhariaYousef
@UIowaCancer
for organizing this.
Although internationally renowned, from a personal perspective- If you did med school in 🇮🇳, there are good chances you read this book cover to cover. I really miss reading textbooks.
Congratulations
@AakashRSheth
,
@SThotamgariMD
and
@UGrewalMD
for getting this important work on the Trends in Cardiovascular Mortality in Patients With Atrial Fibrillation on print...
A big shout out to my amazing mentor/ APD
@PerepuUsha
for allowing me to explore and fine tune my research interest in thrombosis and being so supportive and accommodating always! I am so grateful for your mentorship Dr. Perepu!
@IntMedatIowa
@UIowaCancer
#ASH22
Thrilled to share our latest study on Using Shared Medical Appointments (SMAs) to Deliver Patient-Centered Care to Cancer Survivors, a pilot study performed at our Feist-Weiller Cancer Center
@LSUHS
,
@CesarDC_MD
@SThotamgariMD
@StefanoByer
leads this novel report of a case where we successfully used abatacept and ruxolitinib as salvage therapy for steroid refractory ICI-induced 3M syndrome, out now in the European Journal of Cancer 💊 🩼
@IntMedatIowa
@IM_Iowa
While watching my grandma battle terminal IPF was the toughest time of my life, that experience truly helps me appreciate and understand where my patients & their loved ones come from when they’re angry and frustrated. Having been a caregiver gives you a v different perspective!
Presented our team’s research on the impact of radiation therapy on patients with breast cancer and A Fib as an oral presentation at
@HRSonline
annual meeting 2021. Thanks to my mentors
@drpaari
and Dr. Kavitha Beedupalli and team
@harsh_cardio
and
@AakashRSheth
.
#HRS2021
Sad to be missing out on the amazing CRC sessions at
#GI24
but thanks to the amazing
#GIOnc
community
#medtwitter
for the extremely helpful live updates! This has been a wonderful meeting- endless opportunities and learning! Already excited for
#GI25
!! Until next time…
@ASCO
@DaniyalRaza92
and I discuss the impact of available of primary care providers on HCC- related mortality in 🇺🇸. ⬆️ availability of PCPs ⬇️ HCC-related mortality. We need continued efforts to ⬆️ access to PCPs, especially African Americans.
@LSUHS_IM
Thanks to
@HTRSToday
for a fantastic trainee workshop experience! It was amazing to listen to and learn from legends. Where else can you discuss difficult clinic patients with world renowned experts? Thanks to my mentor Dr. Perepu for this opportunity!
#ASH22
#HTRS
Some of the BEST educators and clinicians who I have worked with have <10 publications after >10 years in academic practice. To change how trainees and young physicians view academia, we need to change the way we measure academic success. What an amazing piece
@THilalMD
!!
Dispatch from
@momilhem
at
#ASCO2023
: Dr. Varun Monga presents data from a recent Phase 1 trial in which
@UIowaCancer
had the most enrolled patients. More to come!
Not sure why
@iamsonalibendre
is being criticised! There is absolutely nothing wrong with establishing a portal for patients (who can afford it) to get a 2nd opinion at a renowned cancer institute. 2nd opinions should always be welcomed. PATIENTS FIRST!
Five years ago, I chose
@MSKCancerCenter
in New York for lifesaving care from a team of oncologists and surgeons. In 2022, I was honoured to cut the ribbon with distinguished guests at MSK’s India centre in Chennai. Today, MSK serves India via a remote
#secondopinion
program, and
Very educational lecture on hormonal management of NETs by
@JaydiDelRivero
. Multidisciplinary management and exploring the entire gamut of available agents in a personalized/patient-centered approach is 🔑.
@NANETS1
Honored to have an opportunity to share our research on colorectal neuroendocrine tumors at
#ASCO23
. Had some great discussions about the topic which made the experience even memorable. Wouldn't have been possible without the kind support and guidance of
@UGrewalMD
🙌🏼